Purpose: To evaluate the efficacy and safety of bimatoprost 0.03 percent given every evening versus timolol maleate 0.5 per-cent/dorzolamide 2 percent fixed combination (TDFC) given twice daily in open-angle glaucoma ...Purpose: To evaluate the efficacy and safety of bimatoprost 0.03 percent given every evening versus timolol maleate 0.5 per-cent/dorzolamide 2 percent fixed combination (TDFC) given twice daily in open-angle glaucoma and ocular hypertensive patients. Design: A single-masked, two center, crossover comparison with two eight-week treatment periods following a four-week medicine free run-in period. Diurnal curve intraoc-展开更多
Purpose: Comparison of the diurnal intraocular pressure (IOP) efficacy and safety of timolol maleate given twice daily versus la?tanoprost given once every evening in patients with exfoliation glaucoma Design: This wa...Purpose: Comparison of the diurnal intraocular pressure (IOP) efficacy and safety of timolol maleate given twice daily versus la?tanoprost given once every evening in patients with exfoliation glaucoma Design: This was a 3-month prospective, single-masked, randomized, placebo-controlled, parallel comparison performed in six hospitals in Greece. We investigated consecutive patients with exfoliation glaucoma, or ocular hypertension and exfoliation syndrome. Patients were randomized to ei-展开更多
The timolol maleate 0.5% /dorzolamide 2% fixed combination (Cosopt) was commercially released in 1998 and is dosed twice daily. Boyle and associates and Clineschmidt and cowork-ers have demonstrated that Cosopt provid...The timolol maleate 0.5% /dorzolamide 2% fixed combination (Cosopt) was commercially released in 1998 and is dosed twice daily. Boyle and associates and Clineschmidt and cowork-ers have demonstrated that Cosopt provided greater intraocular pressure control than timolol maleate 0.5% twice daily, or dorzolamide 2% three times daily, each given alone. Further,展开更多
Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked compa...Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked comparison. Methods: After a 6- week medicine-free period, 33 patients were randomized to receive travoprost dosed in the morning or evening. After 8 weeks of treatment, a 24- hour IOP curve was performed at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am. Patients were then treated with the opposite dosing regimen for another 8 weeks, after which the 24- hour IOP curve was repeated. MainOutcome Measures: Twenty-four-hour IOP. Results: The untreated mean 24- hour IOP was 23.6± 2.0 mmHg. There were no differences for mean 24- hour IOP between the morning (17.5± 1.9mmHg)-and evening (17.3± 1.9 mmHg) dosings (P=0.7). At 10 am, the evening dosing provided a statistically lower IOP (17.2± 2.1 mmHg) than the morning dosing (19.1± 2.5mmHg) (P=0.02). Evening dosing demonstrated a statistically lower 24- hour fluctuation of IOP (3.2± 1.0 mmHg) than morning dosing (4.0± 1.5 mmHg) (P=0.01). Safety was similar, with conjunctival hyperemia being the most common adverse event (n=9 [27% for morning dosing] and n=11 [33% for evening dosing], P=0.6). Conclusions: This study suggests that both morning and evening dosings of travoprost provide effective 24- hour IOP reduction. However, the evening dosing of travoprost demonstrates slightly greater daytime efficacy, with a narrower range of 24- hour pressure.展开更多
Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance....Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance.Methods:A prospective,observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey.Results:Factors that correlated with patient satisfaction included perceived effectiveness of the medicine(F=7.47,P< 0.001),ocular irritation(F=6.06,P< 0.001),conjunctival hyperaemia(F=4.40,P< 0.001),ease of use(F=8.52,P< 0.001),and convenience of use(F=6.90,P < 0.001).Patient compliance,acceptance of their illness,and knowledge of glaucoma were also related to perceived effectiveness of the medicine(P < 0.001),ease of use(P < 0.05)and convenience(P < 0.001).Physician ratings of patient pressure control,side effects,and instillation problems also were significantly correlated to patient satisfaction(R=0.13=0.26,P=0.05-0.001).The physician ratings of patient compliance,however,were not significantly related to any dimension of patient satisfaction(P > 0.05).Among monotherapy prostaglandin treatments,latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia(P < 0.05)and eye irritation(P < 0.01).Conclusions:This study provides initial evidence that patient satisfaction may be related to compliance,perceived effectiveness of treatment,adverse side effects,ease and convenience of use,acceptance of illness,and knowledge of glaucoma.展开更多
文摘Purpose: To evaluate the efficacy and safety of bimatoprost 0.03 percent given every evening versus timolol maleate 0.5 per-cent/dorzolamide 2 percent fixed combination (TDFC) given twice daily in open-angle glaucoma and ocular hypertensive patients. Design: A single-masked, two center, crossover comparison with two eight-week treatment periods following a four-week medicine free run-in period. Diurnal curve intraoc-
文摘Purpose: Comparison of the diurnal intraocular pressure (IOP) efficacy and safety of timolol maleate given twice daily versus la?tanoprost given once every evening in patients with exfoliation glaucoma Design: This was a 3-month prospective, single-masked, randomized, placebo-controlled, parallel comparison performed in six hospitals in Greece. We investigated consecutive patients with exfoliation glaucoma, or ocular hypertension and exfoliation syndrome. Patients were randomized to ei-
文摘The timolol maleate 0.5% /dorzolamide 2% fixed combination (Cosopt) was commercially released in 1998 and is dosed twice daily. Boyle and associates and Clineschmidt and cowork-ers have demonstrated that Cosopt provided greater intraocular pressure control than timolol maleate 0.5% twice daily, or dorzolamide 2% three times daily, each given alone. Further,
文摘Purpose: To evaluate the quality of 24- hour intraocular pressure (IOP) control between morning-and evening-dosed travoprost in primary open-angle glaucoma patients. Design: Prospective, crossover, double-masked comparison. Methods: After a 6- week medicine-free period, 33 patients were randomized to receive travoprost dosed in the morning or evening. After 8 weeks of treatment, a 24- hour IOP curve was performed at 6 am, 10 am, 2 pm, 6 pm, 10 pm, and 2 am. Patients were then treated with the opposite dosing regimen for another 8 weeks, after which the 24- hour IOP curve was repeated. MainOutcome Measures: Twenty-four-hour IOP. Results: The untreated mean 24- hour IOP was 23.6± 2.0 mmHg. There were no differences for mean 24- hour IOP between the morning (17.5± 1.9mmHg)-and evening (17.3± 1.9 mmHg) dosings (P=0.7). At 10 am, the evening dosing provided a statistically lower IOP (17.2± 2.1 mmHg) than the morning dosing (19.1± 2.5mmHg) (P=0.02). Evening dosing demonstrated a statistically lower 24- hour fluctuation of IOP (3.2± 1.0 mmHg) than morning dosing (4.0± 1.5 mmHg) (P=0.01). Safety was similar, with conjunctival hyperemia being the most common adverse event (n=9 [27% for morning dosing] and n=11 [33% for evening dosing], P=0.6). Conclusions: This study suggests that both morning and evening dosings of travoprost provide effective 24- hour IOP reduction. However, the evening dosing of travoprost demonstrates slightly greater daytime efficacy, with a narrower range of 24- hour pressure.
文摘Purpose:To provide initial validation of the Treatment Satisfaction Survey-Intraocular Pressure(TSS-IOP)quality-of-life survey that analyses specific issues related to side effects,patient satisfaction,and compliance.Methods:A prospective,observational cohort of 250 consecutive patients with primary open-angle glaucoma or ocular hypertension was administered the TSS-IOP survey.Results:Factors that correlated with patient satisfaction included perceived effectiveness of the medicine(F=7.47,P< 0.001),ocular irritation(F=6.06,P< 0.001),conjunctival hyperaemia(F=4.40,P< 0.001),ease of use(F=8.52,P< 0.001),and convenience of use(F=6.90,P < 0.001).Patient compliance,acceptance of their illness,and knowledge of glaucoma were also related to perceived effectiveness of the medicine(P < 0.001),ease of use(P < 0.05)and convenience(P < 0.001).Physician ratings of patient pressure control,side effects,and instillation problems also were significantly correlated to patient satisfaction(R=0.13=0.26,P=0.05-0.001).The physician ratings of patient compliance,however,were not significantly related to any dimension of patient satisfaction(P > 0.05).Among monotherapy prostaglandin treatments,latanoprost demonstrated statistically greater satisfaction than bimatoprost or travoprost regarding conjunctival hyperaemia(P < 0.05)and eye irritation(P < 0.01).Conclusions:This study provides initial evidence that patient satisfaction may be related to compliance,perceived effectiveness of treatment,adverse side effects,ease and convenience of use,acceptance of illness,and knowledge of glaucoma.
